Roentgenoendovascular destruction of adrenal glands in the management of primary aldosteronism
DOI:
https://doi.org/10.14739/2310-1210.2019.3.169126Keywords:
hyperaldosteronism, adenoma, hyperplasia, adrenal gland, arterial hypertensionAbstract
Background. In the XXI century, interventional radiology is developing rapidly in the surgical treatment for endocrine pathology of adrenal glands. Until the introduction of aldosterone to renin ratio calculation as a screening test by K. Hiramatsu in 1981, primary aldosteronism was thought to be a rare pathology. Further study of the disease obtained new data on its prevalence – from 5 to 10 % among patients with hypertension and more than 20 % of patients with refractory hypertension. In Ukraine, the prevalence of primary aldosteronism among patients with refractory arterial hypertension is 1.2 %.
The aim of the study was to evaluate the effectiveness of roentgenoendovascular destruction of adrenal glands (REDAG) in patients with primary aldosteronism (PA).
Materials and methods. During the period from 2014 to July2018, a total of 132 patients with adrenal pathology were examined and treated at the Clinic of Hospital Surgery of ZSMU. Operative treatment for primary aldosteronism was performed in 38 patients, including 15 patients who underwent REDAG. There were 10 (66.7 %) women and 5 (33.3 %) men. The average age was 49.4 ± 14.9 years. According to CT (MRT), anatomy of adrenal neoplasms had the following localization: left-sided – in 11 (73.3 %) patients, right-sided – in 1 (6.7 %), bilateral – in 3 (20 %). The mean volume of adrenal neoplasms was 9.0 (6.3–10.0) mm. Diagnostics was performed according to the clinical practical recommendations for the diagnosis and treatment of PA (Clinical Practical Guideline – The Management of Primary Aldosteronism, 2016). Roentgenoendovascular surgery in patients with PA included destruction of the right adrenal gland in 3 (20 %) cases, of the left – in 12 (80 %). The results of the operative treatment were evaluated according to the standard criteria and clinical biochemical criteria of PASO (Primary Aldosteronism Surgical Outcomes) including the echocardiographic data.
Results. The duration of the REDAG was 36.6 ± 6 minutes. Conversions, postoperative complications, lethal outcomes were avoided. The length of hospital stay was 9 (7–12) days. Comparative analysis of surgical treatment results showed a statistically significant decrease in systolic and diastolic blood pressure, aldosterone levels (P < 0.05). The control CT performed after treatment identified adrenal adenomas in the contralateral glands in 2 (13.3 %) patients. However, the follow-up clinical and laboratory diagnostics did not reveal its hormonal activity. According to PASO criteria, the complete biochemical effect was achieved in 73.3 %, complete clinical - in 66.7 %, partial biochemical effect – in 20 %, partial clinical effect – in 26.6 % of patients, failure of biochemical and clinical effects – in 6.7 %.
Conclusions. Interventional methods of surgical treatment for adrenal pathology represent a complete alternative to endoscopic methods of surgical treatment in case if it is clinically indicated. REDAG for primary aldosteronism demonstrates the statistically significant efficacy of symptomatic arterial hypertension treatment: complete biochemical effect in 73.3 %, complete clinical – 66.7%, partial biochemical effect – 20 %, partial clinical effect – 26.6 % of patients.
References
Ierardi, A. M., Petrillo, M., Patella, F., Biondetti, P., Fumarola, E. M., Angileri, S. A., et al. (2018) Interventional radiology of the adrenal glands: current status. Gland Surgery, 7(2), 147–165. doi: 10.21037/gs.2018.01.04
Yamakado, K. (2014) Image-guided ablation of adrenal lesions. Semin Intervent Radiol, 31, 149–56. doi: 10.1055/s-0034-1373797
Fowler, A. M., Burda, J. F., & Kim, S. K. (2013) Adrenal artery embolization: Anatomy, indications, and technical considerations. AJR Am J Roentgenol, 201(1), 190–201. doi: 10.2214/AJR.12.9507
Uppot, R. N., & Gervais, D. A. (2013) Imaging-guided adrenal tumor ablation. AJR Am J Roentgenol, 200(6), 1226–33. doi: 10.2214/AJR.12.10328
Karimov, S. I., Berkinov, U. B., & Sakhiboev, D. P. (2015) The results of treating of adrenal genesis hypertension through different surgical methods. European science review, 11–12, 106–10.
Fowler, A. M., Burda, J. F., & Kim, S. K. (2013) Adrenal artery embolization: anatomy, indications, and technical considerations. AJR Am J Roentgenol., 201(1), 190–201. doi: 10.2214/AJR.12.9507.
Nykonenko, А. O., Zubryk, I. V., Podluzhnyi, А. А., Нaidarzhi, Ye. I., Rusanov, I. V., & Makarenkov, A. L. (2017) Taktyka diahnostyky ta likuvannia patsiientiv iz dvobichnym urazhenniam nadnyrkovykh zaloz, shcho suprovodzhuietsia syndromom pervynnoho hiperaldosteronizmu [Tactic of diagnostic and treatment of patients with bilateral adrenal gland’s lesions associated with primary aldosteronism]. Zaporozhye medical journal, 19, 4(103), 430–435. doi: 10.14739/2310-1210.2017.4.104950 [in Ukrainian].
Morimoto, R., Omata, K., Ito, S., & Satoh, F. (2018) Progress in the Management of Primary Aldosteronism. Am J Hypertens., 31(5), 522–531. doi: 10.1093/ajh/hpy018
Rehan, M., Raizman, J. E., Cavalier, E., Don-Wauchope, A. C., & Holmes, D. T. (2015) Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem., 48(6), 377–87. doi: 10.1016/j.clinbiochem.2015.01.003
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., et al. (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 101(5), 1889–1916. doi: 10.1210/jc.2015-4061
Kline, G. A., Prebtani, A. P. H., Leung, A. A., & Schiffrin, E. L. (2017) Primary aldosteronism: a common cause of resistant hypertension. CMAJ, 189(22), E773–E778. doi: 10.1503/cmaj.161486
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., et al. (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol., 175(2), G1–G34. doi: 10.1530/EJE-16-0467
Paschou, S. A., Vryonidou, A., & Goulis, D. G. (2016) Adrenal incidentalomas: A guide to assessment, treatment and follow-up. Maturitas. 92, 79–85. doi: 10.1016/j.maturitas.2016.07.017
Piaditis, G., Markou, A., Papanastasiou, L., Androulakis, I.I., & Kaltsas, G. (2015) Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol., 172(5), R191–203. doi: 10.1530/EJE-14-0537
Rekovets, O., Torbas, O., Kushnir, S., Ponomareva, G., Primak, G., Granich, V., et al. (2018) Struktura patsiientiv iz rezystentnoiu arterialnoiu hipertenziieiu [Structure of patients with resistant arterial hypertension]. Аrterial'naya gipertenziya, 1(57), 46–66. doi: 10.22141/2224-1485.1.57.2018.125498 [in Ukrainian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
